FACE Phase II (a Stage II Trial)
A Facial Expression-based Personalization Engine (FPE) for Monitoring and Modulating Real-time Effective Engagement in Cognitive Training in Older Adults at Risk for AD/ADRD (CogT FACE Study Phase II)
1 other identifier
interventional
80
1 country
1
Brief Summary
How to ensure adherence to computerized cognitive training in unsupervised circumstances (e.g., at-home, self-administered) in older adults at risk for Alzheimer's disease (AD) or AD related dementia (AD/ADRD) is understudied. The objective of the R33 study is to test a novel facial expression-based personalization engine (FPE) for monitoring and modulating real-time effective engagement, with an ultimate goal of enhancing long-term adherence in unsupervised cognitive training in older adults at risk for AD/ADRD. Here, Effective engagement is defined as the extent to which someone is actively engaged and performing with significant attention and enjoyment while training, addressing a balance between adherence and cognitive gains/plasticity from the training. Based on previous work, the hypotheses include that (1) mental fatigue revealed in facial expressions will reflect a trainee's degree of effective engagement, which can be modified by modulating task novelty; (2) the proposed FPE will ensure the effective engagement in cognitive training by monitoring trainee facial expressions and modulating training in response, promoting the trainee's long-term adherence to the training and cognitive plasticity. A Stage II intervention efficacy study will be conducted to compare effective engagement and adherence in unsupervised cognitive training between training programs with vs. without FPE in older adults at risk for AD/ADRD. The proposed FPE may assist in monitoring and improving effective engagement and adherence in older adults with unsupervised cognitive training. In the current application, FPE in a cognitive training program called speed of processing training will be tested. However, such FPE may be embedded to any computerized cognitive training in future studies to help address adherence related issues.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Oct 2025
Typical duration for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2025
CompletedFirst Posted
Study publicly available on registry
August 19, 2025
CompletedStudy Start
First participant enrolled
October 31, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2028
April 24, 2026
April 1, 2026
2.6 years
August 5, 2025
April 21, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
multi-modal effective engagement index (AID)
facial expression+ECG
up to 8 weeks, throughout the intervention sessions
Secondary Outcomes (4)
the time spent on training
up to 8 weeks, throughout the intervention sessions
self-report perceived fatigue
up to 8 weeks, throughout the intervention sessions
memory
baseline assessment at week 0, post-intervention assessment at week 7, followup assessment at week 13
executive function
baseline assessment at week 0, post-intervention assessment at week 7, followup assessment at week 13
Study Arms (2)
unsupervised cognitive training with personalized engine
EXPERIMENTALtotal 6 week intervention
unsupervised cognitive training without personalized engine
ACTIVE COMPARATORInterventions
computerized cognitive training with a closed-loop human machine interface that monitor facial expression as engagement status of the person
traditional computerized cognitive training
Eligibility Criteria
You may qualify if:
- English speaking
- Aged 60-89
- Living in a home, or independent- or assisted-living facility
- Adequate visual and hearing acuity
- Anti-depressants, antipsychotics, and/or anxiolytics have been stable for at least 7 days
- Memory medications have been stable for at least 3 months
- Absence of neurological/vascular disorder (For neurological disorders with minor symptoms check with PI on case-by-case basis)
You may not qualify if:
- be enrolled in another intervention study aimed at improving cognition
- live in nursing home
- diagnosed with Multiple Sclerosis, TBI, chronic heart failure, Parkinson's disease, dementia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stanford University CogT Lab
Palo Alto, California, 94304-0000, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 5, 2025
First Posted
August 19, 2025
Study Start
October 31, 2025
Primary Completion (Estimated)
May 31, 2028
Study Completion (Estimated)
August 31, 2028
Last Updated
April 24, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share